Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy

1 Nov 2018

Abstract excerpt

Clonal hematopoiesis (CH), in which stem cell clones dominate blood production, becomes increasingly common with age and can presage malignancy development. The conditions that promote ascendancy of particular clones are unclear. We found that mutations in PPM1D (protein phosphatase Mn 2+ /Mg 2+ -dependent 1D), a DNA damage response regulator that is frequently mutated in CH, were present in one-fifth of patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Cancer Genomics and Diagnostics
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30388424
DOI: 10.1016/j.stem.2018.10.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic ChemotherapyPMID 30388424Read ↗

PPM1D in Solid and Hematologic Malignancies: Friend and Foe?Semantic proximity Read ↗

Protein phosphatase, Mg2+/Mn2+-dependent 1D (PPM1D) mutations in haematological cancer.Semantic proximity Read ↗

Clonal Evolution of PPM1D Mutations in the Spectrum of Myeloid DisordersSemantic proximity Read ↗

PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancy.Semantic proximity Read ↗

Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopenias.Semantic proximity Read ↗

Distinct landscape and clinical implications of therapy-related clonal hematopoiesis.Semantic proximity Read ↗

Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes.Semantic proximity Read ↗

Ppm1d truncating mutations promote the development of genotoxic stress-induced AML.Semantic proximity Read ↗

PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cellsSemantic proximity Read ↗

Clonal evolution of hematopoietic stem cells after cancer chemotherapySemantic proximity Read ↗

SOD1 is a synthetic-lethal target in PPM1D-mutant leukemia cells.Semantic proximity Read ↗

Oncologic therapy shapes the fitness landscape of clonal hematopoiesisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.